Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells (Shanghai Genechem)
- Development stage
- Phase 2
- Lead developer
- Shanghai Genechem Co.
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-CD19 CAR-T cells (Shanghai GeneChem) is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of autoimmune diseases, specifically Systemic Lupus Erythematosus (SLE). The therapy involves collecting a patient's T cells and genetically modifying them to express a CAR that recognizes the CD19 protein, a marker found on the surface of B lymphocytes. Once re-infused into the patient, these engineered T cells target and deplete CD19-positive B cells, which are responsible for producing the pathogenic autoantibodies characteristic of SLE. This approach aims to achieve a deep depletion of the B-cell compartment, potentially leading to a "reset" of the immune system and long-term drug-free remission. Shanghai GeneChem is currently evaluating the safety and efficacy of this product in Phase 1 clinical trials for patients with refractory SLE.
- Other names
- CD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsanti-CD19-CAR-T cellsanti-CD-19-CAR-T cellsanti-CD 19-CAR-T cells
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-T cells (Shanghai Genechem).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells (Shanghai Genechem).